Looking Outward — A GenieUs Genomics interview series — As we build GenieUs and our purpose to accelerate diagnostics and therapeutics for neurodegenerative diseases, we like to take inspiration from those pioneers in parrellel spaces. One of those companies is Owkin, the cancer start up that is redefining the cancer space. We have followed Owkin for some time and…

How Can Australia Lead the Way in the Fast Growing Field of Genomics? — By Benjamin Musrie, Medical Researcher. Sydney, Australia. You’ve most likely heard the term ‘genetics’, but what about ‘genomics’? Maybe you use them interchangeably. While this is common, these terms are not synonyms. Both study genetic material and both are derived from the Greek work gen, but the similarities largely end…

Genieus Genomics Whitepaper Series. #1 — By Abdul Karim. Sydney, Australia. Executive summary There is a significant unmet demand for effective therapies for neurodegenerative disease across the world. The diversity of the patient population and the complexity of the molecular pathways producing neuronal degeneration make it difficult to create early diagnostic tools and effective therapies. Scientists, clinicians and…

We aimed to discover a new ALS treatment in just 12 weeks! How did it go? — Last quarter we embarked on an exciting 12-week drug discovery challenge to discover new, efficient and safe treatments for the gruelling neurodegenerative disease, Amyotrophic Lateral Sclerosis (ALS). After continuous hard work which was documented in our weekly blogs, we now proudly look back at the main achievements. The Challenge

Follow at 12wdc.com — By Benjamin Musrie, Medical Researcher. Sydney, Australia. Companies GenieUs Genomics from Sydney, Australia and Arctoris from Oxford, United Kingdom, have joined forces to undertake a first of its kind type challenge — to discover a new ALS treatment in 12 weeks. The two innovative companies believe that the challenge is…

Understanding the molecular transport happening within our neurons is key to developing better therapies for ALS — By Guillaume Troadec. Sydney, Australia. You may know Amyotrophic Lateral Sclerosis (ALS) as the disease that is fundraised by the ice bucket challenge. Or perhaps you know it as the disease that Stephen Hawking suffered from. But what causes it? ALS is a devastating disease where motor neurons in the…

The potential benefits of artificial intelligence are huge, but so are the dangers — Dave Waters — By Benjamin Musrie, Medical Researcher. Sydney, Australia. Artificial intelligence (AI) refers to the simulation of human intelligence by machines, specifically computer systems. These machines can mimic cognitive functions associated with the human brain such as learning, memory, problem-solving and decision-making. The field of AI was born at a conference at…

Your monthly dose of all things ALS! — By Benjamin Musrie, Medical Researcher. Sydney, Australia. GenieUs genomics announced the introduction of their very own newsletter last month — the ‘ALS research roundup’. It is a curated snapshot of recent research in the field of the neurodegenerative disorder — Amyotrophic lateral sclerosis (ALS). …

The pathway has been revealed… — By Benjamin Musrie, Medical Researcher. Sydney, Australia. The human brain is composed of approximately 86 billion neurons (Azevedo et al., 2009). These neurons communicate with one another via endogenous chemical messengers known as neurotransmitters to transmit messages to target cells such as muscle cells, glands and other neurons. Billions of…